Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0040586 (tracheobronchitis)
 449 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A detailed study of a population of dogs with kennel cough was undertaken. Twenty-seven (77 per cent) of a total of 35 dogs had pathological evidence of respiratory disease in the form of tracheobronchitis with, in some animals, exudative pneumonia. A variety of viral and bacterial agents were isolated from the respiratory tract of diseased dogs but Bordetella bronchiseptica and canine parainfluenza virus SV-5 appeared to be the most significant organisms recovered.
 ...
PMID:A study of dogs with kennel cough. 20 6

Bordetella bronchiseptica produced tracheobronchitis when administered in aerosol to specific pathogen-free dogs. Clinical signs appeared to be directly related to numbers of bacteria in the trachea. Electron microscopic examination revealed that each bacterium was close to one or more tracheal cilia and that a fibrillar material was radiating from the bacterial cell wall. B. bronchiseptica required 14 weeks to be cleared from the tracheas of infected dogs; in contrast, other organisms commonly isolated from the respiratory tracts of dogs were cleared within one to three days. Strains of high and low in vitro passage and strains representing three different morphotypes were of equal pathogenicity. Local immunity was observed after infection and appeared to be of primary importance in recovery from the infection. Presumably this response involves prevention of bacterial attachment and reattachment to cilia.
 ...
PMID:Pathogenesis of canine bordetellosis. 40 67

Eight collie-cross pups, eight weeks old, were inoculated intramuscularly with an aluminum hydroxide adjuvanted preparation of killed Bordetella bronchiseptica; the inoculation was repeated after two weeks. Two weeks after the second inoculation, the vaccinated dogs and a control group of four unvaccinated animals were placed in contact with a group of five pups of similar age which had been experimentally infected with a pathogenic strain of B bronchiseptica by an aerosol method. All four unvaccinated control dogs as well as all five experimentally infected dogs developed a respiratory disease characterised by persistent coughing. Six of the vaccinated dogs remained free from clinical respiratory disease while disease was less severe and of shorter duration in the remaining two than in controls. Only slight changes were found in the lungs of vaccinated animals at necropsy while in the controls there was a severe tracheobronchitis. There was a marked reduction in the numbers of B bronchiseptica isolated from the respiratory tract of vaccinated animals when compared with controls. An aluminium hydroxide adjuvanted vaccine may be of value in controlling naturally occurring canine respiratory disease in which B bronchiseptica is involved.
 ...
PMID:Vaccination against canine bordetellosis: protection from contact challenge. 68 92

Six collie dogs, eight weeks old, were inoculated intramuscularly with an aluminium hydroxide adjuvanted preparation of killed Bordetella bronchiseptica; the inoculation was repeated after two weeks. Two weeks after the second inoculation, the vaccinated dogs and a comparable group of six unvaccinated animals were challenged by exposure to an aerosol of pathogenic B bronchiseptica. All six unvaccinated control dogs developed respiratory disease characterised by persistent coughing. In contrast, four of the vaccinated dogs remained free from clinical respiratory disease while, in the other two dogs, disease was less severe and of shorter duration than in controls. At necropsy, there were only slight changes in the lungs of vaccinated dogs but in controls there was a severe tracheobronchitis with areas of exudative pneumonia. Bacteriological examination showed a marked reduction in the numbers of B bronchiseptica isolated from the respiratory tract of vaccinated animals compared with controls. An aluminium hydroxide adjuvant vaccine may be of value in controlling naturally occurring respiratory disease in dogs in which B bronchiseptica is involved.
 ...
PMID:Vaccination against canine bordetellosis using an aluminum hydroxide adjuvant vaccine. 70 49

During the autumn of 1988 an outbreak of canine infectious tracheobronchitis, which seemed to be more infectious than usual, occurred throughout Scandinavia. Paired serum samples and bacterial swabs were collected from 52 dogs with clinical signs of infectious tracheobronchitis in three districts of Norway. The results revealed a fourfold or greater rise in the titre of antibodies against canine parainfluenza virus in 79 per cent of the cases, strongly suggesting that the virus was of aetiological importance in the outbreak. Bordetella bronchiseptica was not isolated from the diseased dogs, and they showed no rise in the titres of antibodies against influenza virus, reovirus or adenovirus.
 ...
PMID:Serological, bacteriological and clinical observations on an outbreak of canine infectious tracheobronchitis in Norway. 216 80

The effect of Bordetella bronchiseptica upper airway colonization on the clinical, radiographic, serologic, pathologic, and pulmonary function changes caused by canine parainfluenza-2 virus (CPIV-2) infection was studied in 24 purebred Beagle pups (10.5 +/- 1.4 weeks old). Eight control dogs (group I) were not colonized or inoculated with CPIV-2. Of the 12 noncolonized dogs inoculated with CPIV-2 (group II), 9 developed antibody titers to CPIV-2 and 10 had clinical signs of infectious canine tracheobronchitis (kennel cough). Group I and group II dogs did not differ in radiographic findings or pulmonary function. Four group II dogs necropsied 1 to 5 days after clinical signs developed had laryngotracheobronchitis and bronchiolar inflammation not present at necropsy on 2 group I dogs. Four dogs had B bronchiseptica upper airway colonization and were inoculated with CPIV-2 (group III). All 4 group III dogs developed positive antibody titers, had clinical signs of kennel cough, and had radiographic changes. Pulmonary dynamic compliance was lower in group III than in group I or group II animals. Respiratory rate and tidal volume did not differ among the 3 groups. The 1 group III dog that was necropsied had changes similar to group II dogs with the addition of lobar bronchopneumonia. The present study indicates that asymptomatic B bronchiseptica colonization may effect the clinical, radiographic, and pulmonary function changes produced by CPIV-2 respiratory tract infections.
 ...
PMID:Role of canine parainfluenza virus and Bordetella bronchiseptica in kennel cough. 609 51

Two field trials were conducted during periods of endemic (summer) and epizootic (winter) canine infectious tracheobronchitis activity to evaluate the efficacy of three intranasal vaccines in a closed commercial beagle breeding kennel. A trivalent vaccine containing Bordetella bronchiseptica, canine parainfluenza, and canine adenovirus-2 was administered at 3 weeks of age. The vaccine was 71.2% and 81.8% effective in decreasing the incidence of coughing during the winter and summer trials, respectively. The number of deaths was lower in each of the vaccine groups than in the placebo groups. No adverse reactions were observed with any of the intranasal vaccines.
 ...
PMID:Intranasal vaccine trial for canine infectious tracheobronchitis (kennel cough). 627 48

A modified-live intranasal (IN) canine parainfluenza (CPI)-virus Bordetella bronchiseptica vaccine was evaluated in dogs for efficacy against laboratory-induced canine infectious tracheobronchitis. The comparative efficacies of IN and parenteral administrations of the CPI virus fraction were also evaluated. The frequency and duration of clinical tracheobronchitis, blood serum agglutination titer, humoral antibody response, and duration of CPI virus and B bronchiseptica shedding were measured. Group A dogs were vaccinated subcutaneously or IM with an experimental CPI vaccine and challenge exposed with CPI virus. Group B dogs were vaccinated IN with avirulent CPI virus-B bronchiseptica live antigens and challenge exposed with virulent CPI virus and virulent B bronchiseptica. The IN vaccination (group B) significantly reduced (P less than or equal to 0.001) the occurrence of clinical tracheobronchitis by 96%. The combined challenge exposure of virulent CPI and virulent B bronchiseptica produced a synergistic enhancement of the clinical signs of kennel cough. The percentage of days after challenge exposure that virus shedding was detected for controls equaled 70% as compared with 50% and only 1% for parenterally and IN vaccinated dogs, respectively. Isolation of virulent B bronchiseptica microorganisms was reduced 89% in dogs vaccinated IN compared to controls. The geometric mean humoral antibody titers to CPI virus after 2 parenteral vaccinations and 1 IN vaccination were 1:43 and 1:34, respectively.
 ...
PMID:Canine infectious tracheobronchitis: effects of an intranasal live canine parainfluenza-Bordetella bronchiseptica vaccine on viral shedding and clinical tracheobronchitis (kennel cough). 627 47

Two Bordetella bronchiseptica isolates, S-55 and D-2, were evaluated in dogs for inducement of (i) infection, (ii) clinical bordetellosis, and (iii) histopathologic changes on tracheal and bronchiole tissues. Further, each isolate was characterized for variance in (i) toxicity for mice and (ii) intracellular proteins. Both S-55 and D-2 were detectable in test dog groups during the 26-day test period, although 545 times more D-2 was recovered than was S-55. In dogs inoculated with D-2, clinical infectious tracheobronchitis appeared in 4 days and continued for 22 days. Bordetellosis was not observed in dogs given S-55 or in noninoculated dogs. Tracheal and bronchiole tissues from dogs inoculated with the S-55 and D-2 isolates were microscopically examined for lesions. Dogs inoculated with S-55 did not have tracheal or bronchiole lesions. Lesions were not observed in noninoculated dogs. Dogs inoculated with D-2 had marked lesions in the tracheal and bronchiole tissues. The D-2 whole cells were an average 4.8 times as lethal as S-55 whole cells in mice (given intraperitoneal inoculation), whereas cell-free culture supernatants from S-55 and D-2 isolates were nontoxic. Cell-free sonicated extracts of S-55 and D-2 proved toxic to mice (intraperitoneal inoculation), but after the extracts were heated at 56 C for 30 minutes, both were nontoxic. Intracellular proteins of approximately 116,000 and 44,000 daltons were found in higher concentration in D-2 cells than in S-55 cells.
 ...
PMID:Comparison of an infective avirulent and canine virulent Bordetella bronchiseptica. 683 9

Dogs inoculated intranasally with a live avirulent Bordetella bronchiseptica vaccine were monitored for the development of resistance to experimentally induced infectious tracheobronchitis (canine cough). Dogs were challenge exposed with a virulent strains of B bronchiseptica at various times after they were vaccinated. Clinical protection was detectable as early as 48 hours. At postvaccination days 4, 5, and 14, 56%, 83%, and 95% protection was observed. Humoral immunoglobulin (Ig) titers ranged from 1:8.6 on day 0 to 1:147 on postvaccination day 21. In the monitoring of B bronchiseptica-specific secretory IgA by indirect immunofluorescence, titers appeared as early as day 4 after vaccination. The IgA titers ranged from 1:16 on day 4 to 1: 1,024 on day 21. The appearance of IgA titers correlated with the development of resistance to clinical infection.
 ...
PMID:Intranasal vaccination of dogs with liver avirulent Bordetella bronchiseptica: correlation of serum agglutination titer and the formation of secretory IgA with protection against experimentally induced infectious tracheobronchitis. 727 Oct 29


1 2 Next >>